In vitro models for testing pancreatic cancer drugs typically involve human pancreatic cancer cell lines cultured in 2D or 3D environments to mimic the tumor microenvironment. In vivo models include genetically engineered mouse models, patient-derived xenografts, and syngeneic models, each designed to assess drug responses and resistance, aiding in the drug development process up to preclinical stages.

Targeted therapy involves drugs that specifically interfere with cancer cell pathways, offering a more precise approach with fewer side effects compared to chemotherapy, which targets all rapidly dividing cells, including healthy ones.

Biomarkers are instrumental in identifying patients likely to benefit from certain drugs, predicting their treatment response, and monitoring treatment effectiveness, thus facilitating personalized medicine.

The process starts with drug discovery and screening, followed by preclinical testing using In vitro and In vivo models. These steps are crucial for assessing the initial safety and efficacy of the drug at the preclinical stage.

Services can include target identification, compound screening, and preclinical testing. These services support the early development stages of the drug, providing a foundation for advancing to further development phases.